Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SANDOZ RECALLING 15,000 CLOZARIL TABLETS DUE TO PACKAGING ERROR

Executive Summary

SANDOZ RECALLING 15,000 CLOZARIL TABLETS DUE TO PACKAGING ERROR involving the company's SandoPak 100 mg unit dose blister- packs. The Class I recall, which was initiated after a pharmacist alerted Sandoz to a problem with the blister-packs, covers four lots of the anti-psychotic. The firm notified pharmacists and wholesalers by mail late last week that because of an error during the packaging process, some of the blister cavities contained two 100 mg tablets of Clozaril instead of one. The manufacturing error apparently occurred after the company changed the vinyl film material used in the blister-packs, which led to uneven filing of the blister cavities. In the letter to pharmacists, Sandoz emphasizes that "patients taking Clozaril (clozapine) should only take the dosage that is prescribed by their physicians in an effort to avoid certain dose- related adverse reactions, such as seizure." The drug also has been associated with the potentially life-threatening side effect of agranulocytosis, a severe reduction in white blood cells. The firm asks pharmacists to visually inspect all Clozaril 100 unit blister-packs before dispensing them to patients. "In some cases where there are two tablets per blister cavity, the tablets may be crushed or cracked, or the bottom tablet may not be readily visible," the company said. Pharmacists are directed to return to Sandoz any blister-packs containing more than one tablet per cavity. On July 30, Sandoz signed a consent agreement with the Federal Trade Commission concerning the company's marketing tactics for Clozaril. The agreement prohibits the firm from "requiring any purchaser of clozapine, or a patient taking clozapine sold by Sandoz, to buy other goods or services from Sandoz or anyone designated by Sandoz." FTC charged Sandoz with illegally requiring purchasers of its schizophrenia drug to buy Sandoz-arranged distribution and patient monitoring services. The final consent agreement contains certain modifications to a June 1991 proposed agreement ("The Pink Sheet" June 24, 1991, T&G-11). Those modifications require Sandoz to provide adverse reaction data to other firms upon request, at a cost of $10 or less. In addition, Sandoz may not "unreasonably withhold" data on clozapine patients from scientists and researchers for a period of eight years and may not charge a fee for such information.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel